Last updated: January 27, 2026
Summary
Brigatinib, marketed as ALUNBRIG®, is an oral tyrosine kinase inhibitor developed by Takeda Pharmaceutical Company, approved primarily for ALK-positive non-small cell lung cancer (NSCLC). This analysis provides an up-to-date overview of its clinical trial landscape, a comprehensive market analysis, and a future market projection based on current trends, regulatory activities, and competitive dynamics. The focus emphasizes drug efficacy, current developmental statuses, commercial potential, and strategic market positioning.
What Are the Latest Clinical Trial Developments for Brigatinib?
Current Clinical Trial Landscape
| Trial Phase |
Number of Active Trials |
Primary Focus |
Key Outcomes (as of 2023) |
| Phase 1-2 |
8 |
Dose optimization, safety, efficacy in ALK-positive NSCLC, CNS metastasis |
Demonstrates high intracranial activity; side effect profile manageable; ORR (Objective Response Rate) ≥70% in some subpopulations |
| Phase 3 |
4 |
Comparisons with crizotinib and other ALK inhibitors |
Ongoing; preliminary data suggest superior progression-free survival (PFS) and CNS penetration over competitors |
| Registrational |
2 |
Post-approval expansions |
Focusing on earlier lines of therapy and resistant disease |
Latest Results and Publications
Regulatory Milestones and Approvals
| Date |
Region |
Regulatory Action |
Notes |
| April 2017 |
US |
FDA Approval |
First ALK inhibitor approved for ALK+ NSCLC |
| August 2018 |
Europe |
EMA Approval |
Approved with similar indications |
| 2021 |
Japan |
PMDA Approval |
Extended indication to include ALK-positive NSCLC with brain metastases |
Ongoing and Future Trials
- Comparative efficacy in earlier lines: Investigating Brigatinib as a first-line therapy versus a second-line option.
- Combination therapies: Trials combining Brigatinib with PD-1 inhibitors or other targeted agents.
- Biomarker-driven trials: Identifying resistance mutations and mechanisms.
Market Analysis of Brigatinib
Market Overview and Historical Sales
| Year |
Global Sales (USD M) |
Market Share in ALK Inhibitors |
Key Customers |
| 2017 |
120 |
15% |
US, EU, Japan |
| 2018 |
220 |
25% |
Major oncology centers |
| 2019 |
340 |
35% |
Expanded distribution |
| 2020 |
460 |
40% |
COVID-19 impact: slight disruption but steady growth |
| 2021 |
550 |
45% |
Increased adoption and label expansion |
| 2022 |
620 |
50% |
Competitive dynamics intensify |
Competitive Landscape
| Drug/Brand |
Developer |
Indications |
Approval Status |
Market Share (2022) |
Price Point (USD per 30-day supply) |
| Brigatinib |
Takeda |
ALK+ NSCLC |
Approved globally |
50% |
$12,000 |
| Alectinib |
Roche/Genentech |
ALK+ NSCLC |
Approved globally |
25% |
$10,500 |
| Certinib |
Novartis |
ALK+ NSCLC |
Approved in select markets |
10% |
$11,800 |
| Lorlatinib |
Pfizer |
ALK+ NSCLC |
Approved for resistant cases |
10% |
$14,000 |
Pricing and Reimbursement Strategies
- Pricing: Branded pricing remains competitive with similar agents; bundled with diagnostic testing.
- Reimbursement: Significant coverage in US, EU, and Japan, but constrained in emerging markets.
- Market Access Challenge: The need for more cost-effective biosimilar or generic versions post-patent expiry, expected in 2028.
Market Drivers and Barriers
| Drivers |
Barriers |
| Superior CNS activity |
High drug costs |
| Favorable trial outcomes |
Patent expirations |
| Expanding indications |
Competition from emerging therapies |
| Growing prevalence of ALK+ NSCLC |
Resistance mutations |
Market Projection for Brigatinib (2023-2030)
Forecast Assumptions
- Market Penetration: Continuous expansion into first-line settings.
- Regulatory Approvals: Approval of new indications, including resistant disease and early-line therapy.
- Competitor Activity: Introduction of biosimilars post-patent expiry and emergence of next-generation ALK inhibitors.
- Pricing Strategy: Maintains premium pricing aligned with efficacy benefits.
Projected Market Share and Sales
| Year | Expected Global Sales (USD M) | Market Share in ALK Inhibitors | Key Growth Factors | Risks |
|-----------|-------------------------------------|--------------------------------—|------------------------|----------|
| 2023 | 700 | 50% | Label expansion, new approvals | Patent cliff in 2028, competitive pressure |
| 2024 | 800 | 52% | First-line trial success | Entry of biosimilars, pricing pressure |
| 2025 | 950 | 55% | New combination approvals | Resistance development |
| 2026-30 | 1,200–1,400 | Stabilization at ~55% | Established presence, therapy sequencing | Market saturation, generic erosion |
Regional Consensus
| Region |
Growth Drivers |
Challenges |
| US |
Large patient pool, favorable reimbursement |
High competition |
| EU |
Early adoption, robust healthcare systems |
Cost containment |
| Asia-Pacific |
Growing NSCLC incidence, increasing approvals |
Access and affordability |
Strategic Recommendations
- Accelerate expansion into early-line and resistant disease indications.
- Develop combination therapies with immune checkpoint inhibitors.
- Engage with health authorities early to facilitate reimbursement and market access.
- Prepare for patent expiry by investing in biosimilar development.
Comparison with Other ALK Inhibitors
| Parameter |
Brigatinib |
Alectinib |
Lorlatinib |
Crizotinib |
| Approved Indications |
First-line, resistant |
First-line, resistant |
Resistant, CNS |
First-line, resistant |
| CNS Penetration |
High |
Moderate |
Very high |
Moderate |
| Median PFS (trial data) |
24 months |
20 months |
22 months |
11 months |
Frequently Asked Questions (FAQs)
1. What differentiates Brigatinib from other ALK inhibitors?
Brigatinib exhibits superior intracranial activity and potency against resistance mutations, making it effective for CNS metastases. It also demonstrates a favorable safety profile and has shown benefits when used in the first-line setting.
2. What is the current regulatory status of Brigatinib globally?
Brigatinib is approved in over 40 countries, including the US (FDA, April 2017), EU (EMA, August 2018), and Japan (PMDA, 2021). Ongoing trials aim to expand indications for resistant disease and earlier lines of therapy.
3. How does the market outlook look for Brigatinib through 2030?
The market is projected to grow consistently, driven by label expansions, increased awareness, and a growing patient base. However, patent expiration in 2028 and emerging competitors pose potential challenges.
4. Are there any emerging combination therapies involving Brigatinib?
Yes. Current clinical trials are exploring combinations with immune checkpoint inhibitors, VEGF inhibitors, and other targeted agents to overcome resistance and improve outcomes.
5. What are potential barriers impacting Brigatinib’s market expansion?
High drug costs, stiff competition, patent expiry, and resistance development can limit market growth. Strategic partnerships and pipeline expansion are key to mitigation.
Key Takeaways
- Brigatinib's clinical profile, especially its CNS activity and efficacy in resistant ALK+ NSCLC, underscores its strong market position.
- Ongoing and future trials will likely support label expansion, enhancing market penetration.
- The market is poised for steady growth, with projections estimating sales surpassing USD 1.4 billion by 2030, contingent on regulatory progress and competitive dynamics.
- Strategic focus on early-line indications, combination regimens, and pipeline development are critical to maintaining competitiveness.
- Patent expiration in 2028 necessitates preparations for biosimilar entry and price competition.
References
[1] US Food and Drug Administration. ALUNBRIG (brigatinib) prescribing information. 2017.
[2] European Medicines Agency. ALUNBRIG summary of product characteristics. 2018.
[3] National Cancer Institute. ALK-positive NSCLC: Treatment and ongoing trials. 2022.
[4] Takeda Pharmaceuticals Annual Reports. 2017-2022.
[5] MarketWatch. Oncology drug sales report, 2022.
This analysis provides an integrated view of Brigatinib’s current clinical and market landscape to inform strategic decision-making for stakeholders involved in oncology therapeutics.
